EP0397831B1 - Traitement de l'obesite - Google Patents

Traitement de l'obesite Download PDF

Info

Publication number
EP0397831B1
EP0397831B1 EP89912801A EP89912801A EP0397831B1 EP 0397831 B1 EP0397831 B1 EP 0397831B1 EP 89912801 A EP89912801 A EP 89912801A EP 89912801 A EP89912801 A EP 89912801A EP 0397831 B1 EP0397831 B1 EP 0397831B1
Authority
EP
European Patent Office
Prior art keywords
trial
treatment
subjects
group
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89912801A
Other languages
German (de)
English (en)
Other versions
EP0397831A1 (fr
Inventor
Monte Lee Scheinbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0397831(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co PLC filed Critical Boots Co PLC
Priority to AT89912801T priority Critical patent/ATE94385T1/de
Publication of EP0397831A1 publication Critical patent/EP0397831A1/fr
Application granted granted Critical
Publication of EP0397831B1 publication Critical patent/EP0397831B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • N , N -dimethyl-1[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride for the manufacture of a medicament for the treatment of obesity, in which treatment the compound is administered in conjunction with a pharmaceutically acceptable diluent or carrier.
  • N , N -dimethvl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine hydrochloride in the treatment of depression is described in British Patent Specification 2098602 and the use of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the treatment of Parkinson's disease is described in published PCT application WO 88/06444.
  • a particularly preferred form of this compound is N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Application 230742.
  • the therapeutically active compound may be administered in any of the known pharmaceutical dosage forms for example solid dosage forms such as tablets or capsules or liquid dosage forms for example those forms intended for oral or parenteral administration.
  • the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 ⁇ mg per day given in one or more doses.
  • sibutramine hydrochloride The ability of sibutramine hydrochloride to cause weight reduction in humans has been demonstrated by the following trials.
  • a first group (Group 1) of 15 subjects were given 2.5 mg sibutramine hydrochloride per day for the first two weeks of the trial, followed by 5 mg sibutramine hydrochloride per day for the remaining four weeks of the trial.
  • the second croup (Group 2) of 15 subjects were given 5 mg sibutramine hydrochloride per day for the first two weeks of the trial, followed by 10 mg sibutramine hydrochloride per day for the remaining four weeks of the trial.
  • the third croup (Group 3) of 9 subjects were given a placebo containing no sibutramine hydrochloride.
  • the subjects were treated with a single dose of sibutramine hydrochloride or placebo taken each morning of the trial.
  • the weight of each subject was taken at the commencement of treatment and after six weeks.
  • a first group (Group 1) of 26 subjects were treated with 10 mg of sibutramine hydrochloride per day for the first two weeks of the trial and then with 20 mg of sibutramine hydrochloride per day for a further period of four weeks.
  • the second group (Group 2) were given a placebo containing no sibutramine hydrochloride every day throughout the trial.
  • the subjects were treated with a single dose of sibutramine hydrochoride or placebo taken each morning of the trial.
  • the weight of each subject was taken at the commencement of the trial and after six weeks.
  • the weight of each subject (in kg) at the start and the change in weight (in kg) over the six week period are given below in Table 2.
  • a first group (Group 1) of 14 subjects were treated with 15 mg of sibutramine hydrochloride per day for the first two weeks of the trial and then with 30 mg of sibutramine hydrochloride for a further period of four weeks.
  • the second group (Group 2) were given a placebo containing no sibutramine hydrochloride every day throughout the trial.
  • the subjects were treated with a single dose of sibutramine hydrochloride or placebo taken each morning of the trial.
  • the weight of each subject was taken at the commencement of the trial and after six weeks.
  • the weight of each subject (in kg) at the start of the trial and the change in weight (in kg) over the six week period arc given below in Table 3.

Abstract

On utilise de l'hydrochlorure de N,N-diméthyle-1-[1-(4-chlorophényle) cyclobutyle]-3-méthylbutylamine dans le traitement de l'obésité chez des sujets humains.

Claims (2)

  1. Utilisation du chlorhydrate de N,N-diméthyl-1-[1-(4-chlorophényl)cyclobutyl]-3-méthylbutylamine dans la préparation d'un médicament destiné au traitement de l'obésité.
  2. Utilisation du chlorhydrate de N,N-diméthyl-1-[1-(4-chlorophénylcyclobutyl]-3-méthylbutylamine monohydraté dans la préparation d'un médicament destiné au traitement de l'obésité.
EP89912801A 1988-11-29 1989-11-21 Traitement de l'obesite Expired - Lifetime EP0397831B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89912801T ATE94385T1 (de) 1988-11-29 1989-11-21 Behandlung von obesitas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29
US277240 1988-11-29

Publications (2)

Publication Number Publication Date
EP0397831A1 EP0397831A1 (fr) 1990-11-22
EP0397831B1 true EP0397831B1 (fr) 1993-09-15

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89912801A Expired - Lifetime EP0397831B1 (fr) 1988-11-29 1989-11-21 Traitement de l'obesite

Country Status (16)

Country Link
US (1) US5436272A (fr)
EP (1) EP0397831B1 (fr)
JP (1) JPH06102622B2 (fr)
KR (1) KR0164435B1 (fr)
AU (1) AU633529B2 (fr)
CA (1) CA2003524C (fr)
DE (2) DE19975039I2 (fr)
DK (1) DK175587B1 (fr)
HK (1) HK1006002A1 (fr)
IE (1) IE61928B1 (fr)
IL (1) IL92406A (fr)
LU (1) LU90866I2 (fr)
NL (1) NL300066I2 (fr)
PH (1) PH26677A (fr)
WO (1) WO1990006110A1 (fr)
ZA (1) ZA899058B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663448B2 (en) 2007-06-04 2017-05-30 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
MXPA01009467A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
JP2002539252A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 胆石の治療
CA2367268A1 (fr) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Perte de poids apres une grossesse
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
WO2000056312A1 (fr) 1999-03-19 2000-09-28 Knoll Gmbh Traitement de l'hypertension arterielle pulmonaire
ES2244420T3 (es) * 1999-03-19 2005-12-16 ABBOTT GMBH & CO. KG Utilizacion de la sibutramina o de uno de sus derivados para el tratamiento de los trastornos del sueño.
NZ514016A (en) * 1999-03-19 2001-09-28 Knoll Gmbh Treatment of osteoarthritis
AU773188C (en) * 1999-03-19 2006-01-05 Abbott Gmbh & Co. Kg Method of treating eating disorders
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
WO2000056311A1 (fr) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Regulation du metabolisme
AU3899100A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056308A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention de maladies cardio-vasculaires
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2002083631A1 (fr) * 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2005028438A1 (fr) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
ES2574014T3 (es) 2005-05-30 2016-06-14 Msd K.K. Derivado de piperidina novedoso
EP1916239A4 (fr) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Composé de pyridone
EP1921065B1 (fr) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Dérivé phénylpyridone
WO2007029847A1 (fr) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Dérivé de pyridone substitué aromatique bicylique
WO2007034910A1 (fr) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. Préparation thérapeutique pour le traitement de la boulimie et de la dépression associée à la boulimie
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
MY146564A (en) 2005-11-10 2012-08-30 Msd Kk Aza-substituted spiro derivatives
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
MX2009002282A (es) 2006-09-07 2009-03-20 Nycomed Gmbh Tratamiento de combinacion para diabetes mellitius.
EP2066329B1 (fr) * 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthèse, utilisation et compositions de cyclobutylméthylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101795684A (zh) * 2007-04-09 2010-08-04 赛多斯有限责任公司 他汀类化合物与抗肥胖药的组合
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2714617A1 (fr) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Derive d'alkylaminopyridine
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP3239170B1 (fr) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2301936A1 (fr) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Dérivé de spirodiamine-diarylcétoxime
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2319841A1 (fr) 2008-07-30 2011-05-11 Msd K.K. Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
CA2741125A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
WO2010065889A2 (fr) * 2008-12-06 2010-06-10 Auspex Pharmaceutical Inhibiteurs cyclobutaneméthanamine de la réabsorption de monoamine
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (fr) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (fr) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
EP3558298A4 (fr) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Burger's Medicinal Chemistry, 4th ed., Part III, 1981, p. 226-228 *
Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th ed., 1990, chapter 10, p. 187-192 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663448B2 (en) 2007-06-04 2017-05-30 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US9670138B2 (en) 2007-06-04 2017-06-06 Ben-Gurion University Of The Negev Research And Development Authority Telomerase activating compounds and methods of use thereof
US10214481B2 (en) 2007-06-04 2019-02-26 Ben-Gurion University Of The Negev Research And Development Aithority Telomerase activating compounds and methods of use thereof
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same

Also Published As

Publication number Publication date
AU633529B2 (en) 1993-02-04
DE68909219D1 (de) 1993-10-21
DE68909219T2 (de) 1994-01-13
JPH02503682A (ja) 1990-11-01
NL300066I2 (nl) 2002-06-03
CA2003524A1 (fr) 1990-05-29
CA2003524C (fr) 1999-10-19
US5436272A (en) 1995-07-25
WO1990006110A1 (fr) 1990-06-14
IE61928B1 (en) 1994-11-30
KR900701261A (ko) 1990-12-01
ZA899058B (en) 1990-08-29
IL92406A (en) 1995-07-31
EP0397831A1 (fr) 1990-11-22
KR0164435B1 (ko) 1999-01-15
HK1006002A1 (en) 1999-02-05
DE19975039I2 (de) 2000-03-30
DK177690A (da) 1990-09-13
DK177690D0 (da) 1990-07-26
PH26677A (en) 1992-09-15
NL300066I1 (nl) 2001-12-01
DK175587B1 (da) 2004-12-13
JPH06102622B2 (ja) 1994-12-14
AU4620789A (en) 1990-06-26
LU90866I2 (fr) 2002-02-18
IE893690L (en) 1990-05-29

Similar Documents

Publication Publication Date Title
EP0397831B1 (fr) Traitement de l'obesite
US5977099A (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US4507323A (en) Treatment of psychosexual dysfunctions
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
EP0123469A1 (fr) Utilisation de fluoxétine pour la préparation d'un médicament contre l'anxiété
US5753712A (en) Treatment of migraine headaches and formulations
US5708036A (en) Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
EP0629400A1 (fr) Compositions contenant de l'idebenone pour le traitement de la maladie d'Alzheimer
EP0171227B1 (fr) Utilisation de propiophénone
EP0813873B1 (fr) Compositions pharmaceutiques comprenants de la mirtazapine et un ou plusieurs inhibiteurs sélectifs d'assimilation de sérotonine
EP0190851B1 (fr) Composition anti-inflammatoire
EP0437026A2 (fr) Utilisation de tandospirone dans le traitement de dépression
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
WO1995022324A1 (fr) Traitement des cephalees migraineuses et formulations
EP3323416B1 (fr) Composition pharmaceutique pour le traitement de l'éjaculation précoce
JPH05201861A (ja) デキストロメトルフアンの鎮咳効果の増強
US4042698A (en) Treatment of myasthenia gravis and oral medication therefor
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
EP0256629A2 (fr) Tolrestat ou l'un de ses sels comme médicament immunostimulant
EP0637956A1 (fr) Utilisatiion de remacemide dans le traitement de la maladie de parkinson
IE55181B1 (en) Treatment of minimal brain dysfunction(mbd)
Rab et al. Double-blind multicentre isradipine dose-confirmation study in Pakistan
Cline et al. Combination antiviral therapy for cytomegalovirus disease in patients with AIDS
US4716177A (en) Tolrestat for inhibition of weight gain
US3773937A (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910705

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19930915

REF Corresponds to:

Ref document number: 94385

Country of ref document: AT

Date of ref document: 19931015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 68909219

Country of ref document: DE

Date of ref document: 19931021

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVE

ET Fr: translation filed
EPTA Lu: last paid annual fee
REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 94385

Country of ref document: AT

Kind code of ref document: T

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8364

Ref document number: 68909219

Country of ref document: DE

Kind code of ref document: A

EAL Se: european patent in force in sweden

Ref document number: 89912801.1

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & WANN PATENTANWALTSBUERO, INHABER KLAUS

Ref country code: CH

Ref legal event code: PUE

Owner name: THE BOOTS COMPANY PLC TRANSFER- KNOLL AG

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

NLS Nl: assignments of ep-patents

Owner name: KNOLL AG

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEIH

Ref document number: 94385

Country of ref document: AT

Kind code of ref document: T

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8327

Ref document number: 68909219

Country of ref document: DE

Kind code of ref document: A

Owner name: KNOLL AG, 67061 LUDWIGSHAFEN, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: V448

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: 41531.00.00, 19990114

Spc suppl protection certif: 199 75 039

Filing date: 19990515

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: CHSPCFOICM-NO 54770/19990113, 19990528

REG Reference to a national code

Ref country code: DE

Ref legal event code: V457

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: 41531.00.00, 19990114

Spc suppl protection certif: 199 75 039

Filing date: 19990515

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: OICM-NO 54770/13.01.1999, 28.05.1999, EXPIRES: 13.01.2014

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: 0190039-8, 20010404

REG Reference to a national code

Ref country code: NL

Ref legal event code: AC1

Free format text: NLAC1 300066, 20011004

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 23 289 20010613; FIRST REGISTRATION: LI - IKS54770 19990113

Spc suppl protection certif: 01C0052

Filing date: 20011210

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: GBCTFFSPC/GB2001/053: 20011109

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: LU

Ref legal event code: CCP

Free format text: LUCCP 90866, EXPIRES: 20140114

REG Reference to a national code

Ref country code: AT

Ref legal event code: ESZA

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID

Spc suppl protection certif: SZ 34/2001

Filing date: 20011023

REG Reference to a national code

Ref country code: NL

Ref legal event code: KC1

Free format text: NLKC1 300066, 20091121, EXPIRES: 20140113

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Spc suppl protection certif: SPC/GB01/053 200210

Filing date: 20021010

Expiry date: 20140112

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEZF

Spc suppl protection certif: SZ 34/2001

Filing date: 20011023

Extension date: 20140113

Effective date: 20020923

BECH Be: change of holder

Owner name: *ABBOTT G.M.B.H. & CO. K.G.

Effective date: 20030225

BECN Be: change of holder's name

Owner name: *ABBOTT G.M.B.H. & CO. K.G.

Effective date: 20030225

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: ABBOTT GMBH & CO. KG

Free format text: KNOLL AG#KNOLLSTRASSE 32#D-67061 LUDWIGSHAFEN (DE) -TRANSFER TO- ABBOTT GMBH & CO. KG#MAX-PLANCK-RING 2#65205 WIESBADEN (DE)

NLS Nl: assignments of ep-patents

Owner name: ABBOTT GMBH

Owner name: KNOLL GMBH

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: ABBOTT GMBH & CO. KG

REG Reference to a national code

Ref country code: NL

Ref legal event code: TC

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8327

Ref document number: 68909219

Country of ref document: DE

Owner name: ABBOTT GMBH & CO. KG, 65205 WIESBADEN, DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0190039-8, 20010404

Spc suppl protection certif: 0190039-8

Filing date: 20010404

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0190039-8

Spc suppl protection certif: 0190039-8

REG Reference to a national code

Ref country code: FR

Ref legal event code: CR

Free format text: 01C0052, 20011210

Spc suppl protection certif: 01C0052

Filing date: 20011210

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEIH

Ref document number: 94385

Country of ref document: AT

Kind code of ref document: T

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CJ

REG Reference to a national code

Ref country code: FR

Ref legal event code: CY

Free format text: PRODUCT NAME: CHLORHYDRATE DE SIBUTRAMINE MONOHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 23289 DU 20010613; REGISTRATION NO/DATE AT EEC: IKS 54770 DU 19990113

Spc suppl protection certif: 01C0052

Filing date: 20011210

Extension date: 20140113

REG Reference to a national code

Ref country code: FR

Spc suppl protection certif: 2001C0052

Ref legal event code: AV

REG Reference to a national code

Ref country code: BE

Ref legal event code: CCCH

Ref document number: 397831

Country of ref document: BE

Owner name: *ABBOT G.M.B.H. + CO. K.G.

Free format text: FORMER OWNER: KNOLL A.G.; PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE (EQUIVALENT TO SIBUTRAMINE FREE BASE)

Spc suppl protection certif: 2001C/041

Filing date: 20011023

Effective date: 20051205

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20081015

Year of fee payment: 20

Ref country code: CH

Payment date: 20081028

Year of fee payment: 20

Ref country code: LU

Payment date: 20081021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20081008

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20081118

Year of fee payment: 20

Ref country code: BE

Payment date: 20081128

Year of fee payment: 20

Ref country code: SE

Payment date: 20081107

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081106

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081128

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081008

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCN

Spc suppl protection certif: C00397831/01

Representative=s name: SCHMAUDER AND PARTNER AG PATENT- UND MARKENANWAELT

BE20 Be: patent expired

Owner name: *ABBOTT G.M.B.H. & CO. K.G.

Effective date: 20091121

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20091120

Ref country code: GB

Ref legal event code: CTFE

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; REGISTERED: DE 41531.00.00 19990114; DE 41531.01.00 19990114; DE 41533.00.00 19990114; DE 41533.01.00 19990114; CH IKS 54770 19990113; UK PL 0169/0129 20010511; UK PL 0169/0130 20010511

Spc suppl protection certif: SPC/GB01/053

Filing date: 20011109

Expiry date: 20091121

Extension date: 20140112

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20091121

REG Reference to a national code

Ref country code: AT

Ref legal event code: EELA

Ref document number: 94385

Country of ref document: AT

Kind code of ref document: T

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20091121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20091120

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

Ref country code: DE

Ref legal event code: R409

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R409

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R409

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCX

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE, IN HET BIJZONDER SIBUTRAMINE HYDROCHLORIDE MONOHYDRAAT; NATL. REGISTRATION NO/DATE: RVG 26281 RVG 26282 20010404; FIRST REGISTRATION: DE 41531.00.00 41531.01.00 41533.01.00 19990114; CH IKS 54770 19990113

Spc suppl protection certif: 300066

Filing date: 20011004

Expiry date: 20091121

Extension date: 20140112

REG Reference to a national code

Ref country code: BE

Ref legal event code: CCRE

Ref document number: 397831

Country of ref document: BE

Owner name: *ABBOT G.M.B.H. + CO. K.G.

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE (EQUIVALENT TO SIBUTRAMINE FREE BASE); NAT. REGISTRATION NO/DATE: 479 IS 53 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113

Spc suppl protection certif: 2001C/041

Filing date: 20040203

Expiry date: 20091121

Extension date: 20140113

Effective date: 20140113

Ref country code: CH

Ref legal event code: SPCL

Spc suppl protection certif: C00397831/01

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCE

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; REGISTERED: DE 41531.00.00 19990114; DE 41531.01.00 19990114; DE 41533.00.00 19990114; DE 41533.01.00 19990114; CH IKS 54770 19990113; UK PL 0169/0129 20010511; UK PL 0169/0130 20010511

Spc suppl protection certif: SPC/GB01/053

Filing date: 20011109

Expiry date: 20091121

Extension date: 20140112

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCX

Ref document number: 94385

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-24052, 1-24053 20010423; FIRST REGISTRATION: LI 54770 19990113

Spc suppl protection certif: 34/2001

Filing date: 20011023

Expiry date: 20091121

Extension date: 20140113

Effective date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R409

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R409

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

Effective date: 20140114

Ref country code: DE

Ref legal event code: R119

Ref document number: 68909219

Country of ref document: DE

Free format text: PRODUCT NAME: SIBUTRAMINHYDROCHLORID-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 41531.00.00 19990114 FIRST REGISTRATION: SCHWEIZ / LIECHTENSTEIN 5477001 5477002 19990113

Spc suppl protection certif: 19975039

Filing date: 19990515

Expiry date: 20091122

Extension date: 20140113

Effective date: 20120601